OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
Read the full story at OpenAI News ↗
Timeline · 5 reports
- 2026-10-20 18:20 · Techmeme
OpenAI acquires Orchestra Bio, which builds AI agents for managing drug development, and plans to integrate its tech into OpenAI life sciences suite Rosalind - 2026-10-20 18:10 · AlphaSignal
OpenAI Buys Orchestra Bio to Push Rosalind Into Drug Development Operations - 2026-10-20 17:55 · Axios AI+
Exclusive: OpenAI has acquired Orchestra Bio - 2026-10-20 13:25 · Techmeme
Arda, which builds AI software and agents to accelerate assembly lines and manufacturing, raised $230M at a $1.5B valuation led by Altimeter, Accel, and Khosla - 2026-10-20 00:00 · OpenAI News
OpenAI acquires Orchestra Bio